VJHemOnc is committed to improving our service to you

VJVirtual | IV vs subcut dara: relevance in COVID-19 pandemic

VJHemOnc is committed to improving our service to you

Rakesh Popat

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, discusses the use of subcutaneous vs intravenous daratumumab, and the importance of a subcutaenous format in light of the COVID-19 pandemic. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter